A Single-centre, Randomized, Double-blind Placebo-controlled, Dose-ascending, Cross-over Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK233705, Formulated With the Excipient Magnesium Stearate, in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Darotropium bromide (Primary)
- Indications Obstructive airway disorders
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 18 Sep 2007 Status changed from recruiting to completed.
- 11 Jun 2007 New trial record.